MRKRHealthcare · BiotechnologyMRKR Stock Forecast: Marker Therapeutics, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Marker Therapeutics, Inc. hold a median 12-month price target of $8 — +477.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 22 Aug 2026 — in the upper half.
MRKR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Marker Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (92): Analysts have, on balance, been raising their forecasts.
Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
MRKR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MRKR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +477.6% from it.
Of the 19 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | $10 |
| 1 Apr 2025 | WBB Securities | Reiterates | Strong Buy | — |
| 5 Mar 2025 | Canaccord Genuity | Initiates | Buy | — |
| 21 Oct 2024 | Ladenburg Thalmann | Maintains | Buy | $11 → $19 |
| 30 Apr 2024 | Ladenburg Thalmann | Initiates | Buy | — |
| 17 Feb 2022 | Roth Capital | Downgrade | Neutral | $3.00 → $1.00 |
| 25 Mar 2021 | Piper Sandler | Initiates | Overweight | — |
| 19 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 12 May 2020 | Piper Sandler | Downgrade | Neutral | $5.00 → $2.50 |
| 13 Nov 2019 | Janney Capital | Maintains | Buy | — |
| 13 Nov 2019 | Janney Montgomery Scott | Maintains | Buy | $15 → $10 |
| 13 Nov 2019 | Piper Jaffray | Maintains | Overweight | — |
| 13 Nov 2019 | Piper Sandler | Maintains | Overweight | $10 → $6.00 |
| 3 July 2019 | Oppenheimer | Initiates | Outperform | — |
| 30 May 2019 | Roth Capital | Initiates | Buy | — |
| 29 Mar 2019 | WBB Securities | Upgrade | Strong Buy | — |
| 1 Mar 2019 | Janney Capital | Initiates | Buy | — |
| 1 Mar 2019 | Janney Montgomery Scott | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MRKR appears on the weeks it earns a place.
MRKR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Marker Therapeutics, Inc. (MRKR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.7×
- Price / sales
- 8.6×
- Price / book
- 1.9×
- EV / EBITDA
- −1.0×
Cheaper than 84% of US stocks
Cheaper than 16% of US stocks
Cheaper than 48% of US stocks
Cheaper than 65% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −385.9%
- Net margin
- 0.0%
Higher than 8% of US stocks
Higher than 30% of US stocks
- Return on equity
- −76.9%
- Return on assets
- −44.1%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MRKR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Marker Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about MRKR stock
What is the MRKR stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Marker Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $5.6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MRKR stock a buy right now?
Of the 3 analysts covering Marker Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Marker Therapeutics, Inc. 59 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MRKR?
As at 22 Aug 2026, Marker Therapeutics, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).
Will MRKR stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +477.6% from the last close, and Ticker Nerd's factor model ranks Marker Therapeutics, Inc. 59 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MRKR stock forecast for 2030?
No analyst covering Marker Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.6 to $10 over the next 12 months.
How has MRKR stock performed over the past year?
Marker Therapeutics, Inc. returned +14.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Marker Therapeutics, Inc. do?
Marker Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapeutic solutions in the pharmaceuticals and biotech sector.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapeutic solutions in the pharmaceuticals and biotech sector. Headquartered in Houston, Texas, and founded in 1999, the company specializes in advancing treatments designed to address significant unmet medical needs. Marker Therapeutics operates within the competitive biotechnology industry, where it engages in research, development, and commercialization of therapeutic products. The company's work spans clinical and preclinical stages, targeting disease areas where novel biological approaches can provide meaningful patient benefits. As a publicly traded biotechnology firm, Marker Therapeutics is subject to the rigorous regulatory and scientific standards that govern drug development and approval. The company maintains operations focused on translating scientific discoveries into effective treatments, contributing to the broader landscape of modern therapeutic innovation and advancing healthcare solutions.
CEO Dr. Juan F. Vera M.D. · 5 employees · United States · https://markertherapeutics.com